Innovation Pharmaceuticals Inc (IPIX)

[biodoc]

Outstanding post, farrell90. Your post should be a sticky. It hits major points regarding limitations of current antivirals, how Brilacidin is different as a virucidal, and how Brilacidin has other properties that set it apart from other therapeutic candidates.

Dexamethasone has demonstrated a small benefit in reducing mortality and in decreasing time to discharge but it's pretty weak and the benefit is only for those with moderate/severe disease who require supplemental oxygen.
https://www.nejm.org/doi/full/10.1056/NEJMoa2021436

Remdesivir doesn't seem to do anything in late Covid but improves time to discharge in less severe cases.

Brilacidin really checks the boxes for what we're looking for in a therapeutic and it's a well designed trial with an appropriate Primary Outcome Measure. I hope the trial is well executed and proves sufficiently powered.

Primary Outcome Measures :
Time to sustained recovery through Day 29 [ Time Frame: Day 1 through Day 29 ]
Day of recovery is defined as the first day on which the subject satisfies one of the following three categories from the ordinal scale with response sustained through Day 29:

Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care (other than for per protocol dosing or assessments, as appropriate);
Not hospitalized, limitation on activities and/or requiring home oxygen;
Not hospitalized, no limitations on activities.